CSPG4 and melanoma: Regarding A-1155463, while it did not affect melanoma cell viability, it increased the effect of immunotoxin targeting the melanoma-associated chondroitin sulfate proteoglycan 4 (CSPG4) when combined with the Mcl-1 specific inhibitor, S63845 [129].